loading page

Surgery with emicizumab prophylaxis for two pediatric patients with severe haemophilia A with inhibitors
  • +3
  • Marguerite Lockhart,
  • Brigitte TARDY-PONCET,
  • Aurélie Montmartin,
  • Pauline Noyel,
  • Sandrine Thouvenin-Doulet,
  • Claire Berger
Marguerite Lockhart
CHU Saint-Étienne
Author Profile
Brigitte TARDY-PONCET
EA 3065, Université Jean-Monnet, INSERM CIC 1408
Author Profile
Aurélie Montmartin
U1059 INSERM
Author Profile
Pauline Noyel
CHU Saint-Étienne
Author Profile
Sandrine Thouvenin-Doulet
University Hospital, Saint Etienne
Author Profile
Claire Berger
CHU Saint-Étienne
Author Profile

Abstract

Emicizumab is a prophylaxis for patients with severe haemophilia A with inhibitor. Despite the daily prophylaxis, coagulation states stay below normal value and cannot be assessed by standard hemostasis techniques. In our two patients, we use thrombin generation assay (endogenous thrombin potential (ETP) and Peak) to monitor the patient’s clotting status. Under emicizumab, it is needed to add by-passing agent such as FVIIa (Novoseven®) to avoid bleeding before surgery. By-passing agent dose was chosen with the help of thrombin generation assay and after collegial concertation.

Peer review status:ACCEPTED

11 Nov 2020Submission Checks Completed
11 Nov 2020Assigned to Editor
11 Nov 2020Submitted to Pediatric Blood & Cancer
16 Nov 2020Reviewer(s) Assigned
29 Nov 2020Review(s) Completed, Editorial Evaluation Pending
09 Dec 2020Editorial Decision: Revise Major
28 Jan 20211st Revision Received
28 Jan 2021Assigned to Editor
28 Jan 2021Submission Checks Completed
02 Feb 2021Reviewer(s) Assigned
11 Feb 2021Review(s) Completed, Editorial Evaluation Pending
17 Feb 2021Editorial Decision: Revise Minor
04 Mar 2021Submission Checks Completed
04 Mar 2021Assigned to Editor
04 Mar 20212nd Revision Received
07 Mar 2021Reviewer(s) Assigned
14 Mar 2021Review(s) Completed, Editorial Evaluation Pending
15 Mar 2021Editorial Decision: Accept